

Steve Manobianco joins Abzyme Therapeutics as Director of Business Development

Royersford, PA, December 12, 2016. Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic application, is pleased to announce the appointment of Steve Manobianco in the role of Director of Business Development.

Steve has an impressive background in global sales, business development and strategic marketing. For a significant part of his professional career Steve has been working in the pharmaceutical R&D service industry. Steve has a broad knowledge and working experience in the global research and development marketplace.

“I couldn’t be happier to have such a seasoned professional as Steve to be our new team member,” said Hiep Tran, PhD, Abzyme’s co-founder and president. “Steve’s deep knowledge of the biopharmaceutical industry in both business development, sales and marketing will be an invaluable asset to Abzyme Therapeutics as we enter our 7th year in business.”

Steve has a successful track record of creating and executing go-to-market business development strategies to effectively drive double digit revenue growth. Prior to joining Abzyme, he was the Vice President of Global Sales and Business Development for GENEWIZ. Steve holds a Bachelor’s degree in Economics from Syracuse University and an MBA from Regis University, Denver Colorado.

For further information, please contact:

Abzyme Therapeutics LLC

Rolf K. Swoboda, PhD.

Director of Antibody Development and Production

Phone: 610-990-7531

E-mail: swoboda@abzymetx.com